Leqvio, a medication for lowering cholesterol, received U.S. Food and Drug Administration (FDA) approval on December 22, 2020. [1] The drug is indicated for adults with high cholesterol, specifically those with elevated LDL-C levels, who are on maximally tolerated statin therapy or for whom statins are not indicated. [1] It is also approved for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who are on a statin and/or ezetimibe. [1]
How does Leqvio work to lower cholesterol?
Leqvio targets PCSK9, a protein that reduces the number of LDL receptors in the liver. By inhibiting PCSK9, Leqvio increases the number of LDL receptors available to remove LDL cholesterol from the blood. [1] It is administered as a subcutaneous injection. [1]
What is the prescribing information for Leqvio?
Leqvio is administered by a healthcare professional. The recommended dosage is an initial dose of 600 mg, followed by a second 600 mg dose three months later. [1] After the initial two doses, it is administered every six months. [1]
Who manufactures Leqvio?
Leqvio is manufactured by Novartis. [1]
When does Leqvio's patent protection end?
Patent protection for Leqvio is a complex issue involving multiple patents. Information regarding specific patent expiry dates and potential challenges can be found on resources like DrugPatentWatch.com. [2]
Are there any alternative treatments for high cholesterol?
Several alternative and complementary treatments exist for high cholesterol. These include statins, ezetimibe, bile acid sequestrants, and fibrates. Lifestyle modifications such as diet and exercise are also crucial components of cholesterol management. [3] Patients and healthcare providers consider various factors, including efficacy, tolerability, and co-existing medical conditions, when choosing the most appropriate treatment.